Advertisement
UK markets closed

  • FTSE 100

    8,420.26
    -18.39 (-0.22%)
     

  • FTSE 250

    20,749.90
    -72.94 (-0.35%)
     

  • AIM

    794.02
    +1.52 (+0.19%)
     

  • GBP/EUR

    1.1678
    +0.0023 (+0.20%)
     

  • GBP/USD

    1.2706
    +0.0035 (+0.28%)
     

  • Bitcoin GBP

    52,819.94
    +211.36 (+0.40%)
     

  • CMC Crypto 200

    1,371.98
    -1.87 (-0.14%)
     

  • S&P 500

    5,303.27
    +6.17 (+0.12%)
     

  • DOW

    40,003.59
    +134.21 (+0.34%)
     

  • CRUDE OIL

    80.00
    +0.77 (+0.97%)
     

  • GOLD FUTURES

    2,419.80
    +34.30 (+1.44%)
     

  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     

  • HANG SENG

    19,553.61
    +177.08 (+0.91%)
     

  • DAX

    18,704.42
    -34.39 (-0.18%)
     

  • CAC 40

    8,167.50
    -20.99 (-0.26%)
     

GlaxoSmithKline lung drug Anoro approved in Europe

Reuters - UK Focus

LONDON, May 8 (Reuters) - GlaxoSmithKline (Other OTC: GLAXF - news) said on Thursday its new inhaled lung drug, Anoro, had been approved in Europe as a treatment for chronic lung disease, boosting its respiratory franchise.

A final green light had been expected for the product, which was developed with Theravance (NasdaqGS: THRX - news) , following a recommendation from European experts in February.

Respiratory drugs are a major business for GSK. Advair or Seretide, its market-leading lung drug, makes up a fifth of its sales, but it is already facing competition from generic versions in Europe.

Industry analysts expect Anoro to generate worldwide annual sales of about $2.65 billion by 2019, according to Thomson Reuters data. (Reporting by Ben Hirschler; editing by Jane Baird)